Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo (ALBO) Up on Results From Alagille Syndrome Study
01:32pm, Wednesday, 12'th Oct 2022
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder
09:29am, Tuesday, 11'th Oct 2022
Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a tre
Albireo Pharma: Assessing The Sagard Deal
11:05am, Monday, 03'rd Oct 2022
Albireo Pharma, Inc. is expanding its Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. The company is poised to report topline data for the Phase 3 (ASSERT) tri
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?
09:47am, Friday, 23'rd Sep 2022
Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te
Albireo to Participate in Upcoming Investor Conferences
08:00am, Thursday, 01'st Sep 2022
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today an
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2022 Results - Earnings Call Transcript
09:31pm, Monday, 15'th Aug 2022
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Ron Cooper - CEO, President & Director Pamela Step
Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates
06:48pm, Monday, 15'th Aug 2022
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
11:18am, Thursday, 11'th Aug 2022
Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
10:49am, Monday, 25'th Jul 2022
Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
03:50pm, Friday, 22'nd Jul 2022
Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which
Albireo to Present at the William Blair Biotech Focus Conference 2022
08:00am, Thursday, 30'th Jun 2022
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Bi
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
08:30am, Tuesday, 07'th Jun 2022
– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat)
Albireo to Participate at Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Jun 2022
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
04:30pm, Thursday, 19'th May 2022
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright G
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript
10:59pm, Monday, 16'th May 2022
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-LifeSci Advisors, LLC Ron Cooper - President & Chief
